カテゴリー： Market Monitor Global, 世界, 医療/バイオ

希少疾病用治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Orphan Indication Treatment Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5857）

◆商品コード：MMG23JU5857
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：77
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Orphan Indication Treatment Market 調査レポートは次の情報を含め、グローバルにおけるの希少疾病用治療薬市場規模と予測を収録しています。・世界の希少疾病用治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の希少疾病用治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の希少疾病用治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイオ医薬品」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

希少疾病用治療薬のグローバル主要企業は、Bristol-Myers Squibb、 Roche、 Novartis、 Johnson & Johnson、 Pfizer、 Amgen、 Sanofi、 AstraZeneca、 Takeda、 Vertex Pharmaceuticals、 AbbVie、 Biogen、 Eli Lillyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、希少疾病用治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の希少疾病用治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の希少疾病用治療薬市場：タイプ別市場シェア、2022年
・バイオ医薬品、非バイオ医薬品

世界の希少疾病用治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の希少疾病用治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン販売

世界の希少疾病用治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の希少疾病用治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における希少疾病用治療薬のグローバル売上、2018年-2023年
・主要企業における希少疾病用治療薬のグローバル売上シェア、2022年
・主要企業における希少疾病用治療薬のグローバル販売量、2018年-2023年
・主要企業における希少疾病用治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Bristol-Myers Squibb、 Roche、 Novartis、 Johnson & Johnson、 Pfizer、 Amgen、 Sanofi、 AstraZeneca、 Takeda、 Vertex Pharmaceuticals、 AbbVie、 Biogen、 Eli Lilly

*************************************************************

・調査・分析レポートの概要
希少疾病用治療薬市場の定義
市場セグメント
世界の希少疾病用治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の希少疾病用治療薬市場規模
世界の希少疾病用治療薬市場規模：2022年 VS 2029年
世界の希少疾病用治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの希少疾病用治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の希少疾病用治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：バイオ医薬品、非バイオ医薬品
希少疾病用治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、オンライン販売
希少疾病用治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別希少疾病用治療薬市場規模 2022年と2029年
地域別希少疾病用治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Bristol-Myers Squibb、 Roche、 Novartis、 Johnson & Johnson、 Pfizer、 Amgen、 Sanofi、 AstraZeneca、 Takeda、 Vertex Pharmaceuticals、 AbbVie、 Biogen、 Eli Lilly
...

An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as “orphan” is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.
This report aims to provide a comprehensive presentation of the global market for Orphan Indication Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orphan Indication Treatment. This report contains market size and forecasts of Orphan Indication Treatment in global, including the following market information:
Global Orphan Indication Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Orphan Indication Treatment Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Orphan Indication Treatment companies in 2022 (%)
The global Orphan Indication Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Biologics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Orphan Indication Treatment include Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, AstraZeneca and Takeda, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Orphan Indication Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Orphan Indication Treatment Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Orphan Indication Treatment Market Segment Percentages, by Type, 2022 (%)
Biologics
Non-Biologics
Global Orphan Indication Treatment Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Orphan Indication Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Online Sales
Global Orphan Indication Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Orphan Indication Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Orphan Indication Treatment revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Orphan Indication Treatment revenues share in global market, 2022 (%)
Key companies Orphan Indication Treatment sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Orphan Indication Treatment sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Outline of Major Chapters:
Chapter 1: Introduces the definition of Orphan Indication Treatment, market overview.
Chapter 2: Global Orphan Indication Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Orphan Indication Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Orphan Indication Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Orphan Indication Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Orphan Indication Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Orphan Indication Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Orphan Indication Treatment Overall Market Size
2.1 Global Orphan Indication Treatment Market Size: 2022 VS 2029
2.2 Global Orphan Indication Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Orphan Indication Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top Orphan Indication Treatment Players in Global Market
3.2 Top Global Orphan Indication Treatment Companies Ranked by Revenue
3.3 Global Orphan Indication Treatment Revenue by Companies
3.4 Global Orphan Indication Treatment Sales by Companies
3.5 Global Orphan Indication Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Orphan Indication Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Orphan Indication Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 Orphan Indication Treatment Players in Global Market
3.8.1 List of Global Tier 1 Orphan Indication Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 Orphan Indication Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Orphan Indication Treatment Market Size Markets, 2022 & 2029
4.1.2 Biologics
4.1.3 Non-Biologics
4.2 By Type – Global Orphan Indication Treatment Revenue & Forecasts
4.2.1 By Type – Global Orphan Indication Treatment Revenue, 2018-2023
4.2.2 By Type – Global Orphan Indication Treatment Revenue, 2024-2029
4.2.3 By Type – Global Orphan Indication Treatment Revenue Market Share, 2018-2029
4.3 By Type – Global Orphan Indication Treatment Sales & Forecasts
4.3.1 By Type – Global Orphan Indication Treatment Sales, 2018-2023
4.3.2 By Type – Global Orphan Indication Treatment Sales, 2024-2029
4.3.3 By Type – Global Orphan Indication Treatment Sales Market Share, 2018-2029
4.4 By Type – Global Orphan Indication Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Orphan Indication Treatment Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Sales
5.2 By Application – Global Orphan Indication Treatment Revenue & Forecasts
5.2.1 By Application – Global Orphan Indication Treatment Revenue, 2018-2023
5.2.2 By Application – Global Orphan Indication Treatment Revenue, 2024-2029
5.2.3 By Application – Global Orphan Indication Treatment Revenue Market Share, 2018-2029
5.3 By Application – Global Orphan Indication Treatment Sales & Forecasts
5.3.1 By Application – Global Orphan Indication Treatment Sales, 2018-2023
5.3.2 By Application – Global Orphan Indication Treatment Sales, 2024-2029
5.3.3 By Application – Global Orphan Indication Treatment Sales Market Share, 2018-2029
5.4 By Application – Global Orphan Indication Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Orphan Indication Treatment Market Size, 2022 & 2029
6.2 By Region – Global Orphan Indication Treatment Revenue & Forecasts
6.2.1 By Region – Global Orphan Indication Treatment Revenue, 2018-2023
6.2.2 By Region – Global Orphan Indication Treatment Revenue, 2024-2029
6.2.3 By Region – Global Orphan Indication Treatment Revenue Market Share, 2018-2029
6.3 By Region – Global Orphan Indication Treatment Sales & Forecasts
6.3.1 By Region – Global Orphan Indication Treatment Sales, 2018-2023
6.3.2 By Region – Global Orphan Indication Treatment Sales, 2024-2029
6.3.3 By Region – Global Orphan Indication Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Orphan Indication Treatment Revenue, 2018-2029
6.4.2 By Country – North America Orphan Indication Treatment Sales, 2018-2029
6.4.3 US Orphan Indication Treatment Market Size, 2018-2029
6.4.4 Canada Orphan Indication Treatment Market Size, 2018-2029
6.4.5 Mexico Orphan Indication Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Orphan Indication Treatment Revenue, 2018-2029
6.5.2 By Country – Europe Orphan Indication Treatment Sales, 2018-2029
6.5.3 Germany Orphan Indication Treatment Market Size, 2018-2029
6.5.4 France Orphan Indication Treatment Market Size, 2018-2029
6.5.5 U.K. Orphan Indication Treatment Market Size, 2018-2029
6.5.6 Italy Orphan Indication Treatment Market Size, 2018-2029
6.5.7 Russia Orphan Indication Treatment Market Size, 2018-2029
6.5.8 Nordic Countries Orphan Indication Treatment Market Size, 2018-2029
6.5.9 Benelux Orphan Indication Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Orphan Indication Treatment Revenue, 2018-2029
6.6.2 By Region – Asia Orphan Indication Treatment Sales, 2018-2029
6.6.3 China Orphan Indication Treatment Market Size, 2018-2029
6.6.4 Japan Orphan Indication Treatment Market Size, 2018-2029
6.6.5 South Korea Orphan Indication Treatment Market Size, 2018-2029
6.6.6 Southeast Asia Orphan Indication Treatment Market Size, 2018-2029
6.6.7 India Orphan Indication Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Orphan Indication Treatment Revenue, 2018-2029
6.7.2 By Country – South America Orphan Indication Treatment Sales, 2018-2029
6.7.3 Brazil Orphan Indication Treatment Market Size, 2018-2029
6.7.4 Argentina Orphan Indication Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Orphan Indication Treatment Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Orphan Indication Treatment Sales, 2018-2029
6.8.3 Turkey Orphan Indication Treatment Market Size, 2018-2029
6.8.4 Israel Orphan Indication Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia Orphan Indication Treatment Market Size, 2018-2029
6.8.6 UAE Orphan Indication Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Orphan Indication Treatment Major Product Offerings
7.1.4 Bristol-Myers Squibb Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Orphan Indication Treatment Major Product Offerings
7.2.4 Roche Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Orphan Indication Treatment Major Product Offerings
7.3.4 Novartis Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Orphan Indication Treatment Major Product Offerings
7.4.4 Johnson & Johnson Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Orphan Indication Treatment Major Product Offerings
7.5.4 Pfizer Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Orphan Indication Treatment Major Product Offerings
7.6.4 Amgen Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Sanofi
7.7.1 Sanofi Company Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Orphan Indication Treatment Major Product Offerings
7.7.4 Sanofi Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.7.5 Sanofi Key News & Latest Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Company Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Orphan Indication Treatment Major Product Offerings
7.8.4 AstraZeneca Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.8.5 AstraZeneca Key News & Latest Developments
7.9 Takeda
7.9.1 Takeda Company Summary
7.9.2 Takeda Business Overview
7.9.3 Takeda Orphan Indication Treatment Major Product Offerings
7.9.4 Takeda Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.9.5 Takeda Key News & Latest Developments
7.10 Vertex Pharmaceuticals
7.10.1 Vertex Pharmaceuticals Company Summary
7.10.2 Vertex Pharmaceuticals Business Overview
7.10.3 Vertex Pharmaceuticals Orphan Indication Treatment Major Product Offerings
7.10.4 Vertex Pharmaceuticals Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.10.5 Vertex Pharmaceuticals Key News & Latest Developments
7.11 AbbVie
7.11.1 AbbVie Company Summary
7.11.2 AbbVie Orphan Indication Treatment Business Overview
7.11.3 AbbVie Orphan Indication Treatment Major Product Offerings
7.11.4 AbbVie Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.11.5 AbbVie Key News & Latest Developments
7.12 Biogen
7.12.1 Biogen Company Summary
7.12.2 Biogen Orphan Indication Treatment Business Overview
7.12.3 Biogen Orphan Indication Treatment Major Product Offerings
7.12.4 Biogen Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.12.5 Biogen Key News & Latest Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Company Summary
7.13.2 Eli Lilly Orphan Indication Treatment Business Overview
7.13.3 Eli Lilly Orphan Indication Treatment Major Product Offerings
7.13.4 Eli Lilly Orphan Indication Treatment Sales and Revenue in Global (2018-2023)
7.13.5 Eli Lilly Key News & Latest Developments
8 Global Orphan Indication Treatment Production Capacity, Analysis
8.1 Global Orphan Indication Treatment Production Capacity, 2018-2029
8.2 Orphan Indication Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global Orphan Indication Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Orphan Indication Treatment Supply Chain Analysis
10.1 Orphan Indication Treatment Industry Value Chain
10.2 Orphan Indication Treatment Upstream Market
10.3 Orphan Indication Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Orphan Indication Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Orphan Indication Treatment in Global Market
Table 2. Top Orphan Indication Treatment Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Orphan Indication Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Orphan Indication Treatment Revenue Share by Companies, 2018-2023
Table 5. Global Orphan Indication Treatment Sales by Companies, (K Units), 2018-2023
Table 6. Global Orphan Indication Treatment Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Orphan Indication Treatment Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Orphan Indication Treatment Product Type
Table 9. List of Global Tier 1 Orphan Indication Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Orphan Indication Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Orphan Indication Treatment Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Orphan Indication Treatment Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Orphan Indication Treatment Sales (K Units), 2018-2023
Table 15. By Type - Global Orphan Indication Treatment Sales (K Units), 2024-2029
Table 16. By Application – Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Orphan Indication Treatment Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Orphan Indication Treatment Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Orphan Indication Treatment Sales (K Units), 2018-2023
Table 20. By Application - Global Orphan Indication Treatment Sales (K Units), 2024-2029
Table 21. By Region – Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Orphan Indication Treatment Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Orphan Indication Treatment Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Orphan Indication Treatment Sales (K Units), 2018-2023
Table 25. By Region - Global Orphan Indication Treatment Sales (K Units), 2024-2029
Table 26. By Country - North America Orphan Indication Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Orphan Indication Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Orphan Indication Treatment Sales, (K Units), 2018-2023
Table 29. By Country - North America Orphan Indication Treatment Sales, (K Units), 2024-2029
Table 30. By Country - Europe Orphan Indication Treatment Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Orphan Indication Treatment Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Orphan Indication Treatment Sales, (K Units), 2018-2023
Table 33. By Country - Europe Orphan Indication Treatment Sales, (K Units), 2024-2029
Table 34. By Region - Asia Orphan Indication Treatment Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Orphan Indication Treatment Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Orphan Indication Treatment Sales, (K Units), 2018-2023
Table 37. By Region - Asia Orphan Indication Treatment Sales, (K Units), 2024-2029
Table 38. By Country - South America Orphan Indication Treatment Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Orphan Indication Treatment Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Orphan Indication Treatment Sales, (K Units), 2018-2023
Table 41. By Country - South America Orphan Indication Treatment Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Orphan Indication Treatment Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Orphan Indication Treatment Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Orphan Indication Treatment Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Orphan Indication Treatment Sales, (K Units), 2024-2029
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Orphan Indication Treatment Product Offerings
Table 48. Bristol-Myers Squibb Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Roche Company Summary
Table 51. Roche Orphan Indication Treatment Product Offerings
Table 52. Roche Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Roche Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Orphan Indication Treatment Product Offerings
Table 56. Novartis Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Johnson & Johnson Company Summary
Table 59. Johnson & Johnson Orphan Indication Treatment Product Offerings
Table 60. Johnson & Johnson Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Johnson & Johnson Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Orphan Indication Treatment Product Offerings
Table 64. Pfizer Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Amgen Company Summary
Table 67. Amgen Orphan Indication Treatment Product Offerings
Table 68. Amgen Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Amgen Key News & Latest Developments
Table 70. Sanofi Company Summary
Table 71. Sanofi Orphan Indication Treatment Product Offerings
Table 72. Sanofi Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Sanofi Key News & Latest Developments
Table 74. AstraZeneca Company Summary
Table 75. AstraZeneca Orphan Indication Treatment Product Offerings
Table 76. AstraZeneca Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. AstraZeneca Key News & Latest Developments
Table 78. Takeda Company Summary
Table 79. Takeda Orphan Indication Treatment Product Offerings
Table 80. Takeda Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Takeda Key News & Latest Developments
Table 82. Vertex Pharmaceuticals Company Summary
Table 83. Vertex Pharmaceuticals Orphan Indication Treatment Product Offerings
Table 84. Vertex Pharmaceuticals Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Vertex Pharmaceuticals Key News & Latest Developments
Table 86. AbbVie Company Summary
Table 87. AbbVie Orphan Indication Treatment Product Offerings
Table 88. AbbVie Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. AbbVie Key News & Latest Developments
Table 90. Biogen Company Summary
Table 91. Biogen Orphan Indication Treatment Product Offerings
Table 92. Biogen Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Biogen Key News & Latest Developments
Table 94. Eli Lilly Company Summary
Table 95. Eli Lilly Orphan Indication Treatment Product Offerings
Table 96. Eli Lilly Orphan Indication Treatment Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Eli Lilly Key News & Latest Developments
Table 98. Orphan Indication Treatment Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 99. Global Orphan Indication Treatment Capacity Market Share of Key Manufacturers, 2021-2023
Table 100. Global Orphan Indication Treatment Production by Region, 2018-2023 (K Units)
Table 101. Global Orphan Indication Treatment Production by Region, 2024-2029 (K Units)
Table 102. Orphan Indication Treatment Market Opportunities & Trends in Global Market
Table 103. Orphan Indication Treatment Market Drivers in Global Market
Table 104. Orphan Indication Treatment Market Restraints in Global Market
Table 105. Orphan Indication Treatment Raw Materials
Table 106. Orphan Indication Treatment Raw Materials Suppliers in Global Market
Table 107. Typical Orphan Indication Treatment Downstream
Table 108. Orphan Indication Treatment Downstream Clients in Global Market
Table 109. Orphan Indication Treatment Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Orphan Indication Treatment Segment by Type in 2022
Figure 2. Orphan Indication Treatment Segment by Application in 2022
Figure 3. Global Orphan Indication Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Orphan Indication Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Orphan Indication Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. Orphan Indication Treatment Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Orphan Indication Treatment Revenue in 2022
Figure 9. By Type - Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 11. By Type - Global Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 12. By Type - Global Orphan Indication Treatment Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 15. By Application - Global Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 16. By Application - Global Orphan Indication Treatment Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Orphan Indication Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Orphan Indication Treatment Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 20. By Region - Global Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 21. By Country - North America Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 22. By Country - North America Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 23. US Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 28. Germany Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. France Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 37. China Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. India Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 43. By Country - South America Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 44. Brazil Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Orphan Indication Treatment Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Orphan Indication Treatment Sales Market Share, 2018-2029
Figure 48. Turkey Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Orphan Indication Treatment Revenue, (US$, Mn), 2018-2029
Figure 52. Global Orphan Indication Treatment Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Orphan Indication Treatment by Region, 2022 VS 2029
Figure 54. Orphan Indication Treatment Industry Value Chain
Figure 55. Marketing Channels

※参考情報

希少疾病用治療薬、つまりオーファンインディケーション治療薬は、希少疾病の治療のために開発された医薬品を指します。希少疾病とは、一般的に患者数が少ない疾患を指し、多くの場合、人口の約2,000人に1人未満の罹病率を持つ疾患として定義されます。これらの疾患に対する治療薬は、市場の規模が小さいために開発されにくいという特性があり、そのため希少疾病用の治療薬の開発が必要とされています。

希少疾病用治療薬の特徴は、以下のような点に挙げられます。第一に、臨床試験のデザインが特異であることです。希少疾病は例が少ないため、大規模な臨床試験の実施が難しく、通常は小規模な試験やデザインの工夫が求められます。第二に、治療の様式が個別化されることも特徴です。患者ごとに疾患の進行や反応が異なるため、個別の治療が重要視されます。第三に、治療薬の価格が高くなりがちである点も重要です。開発コストを回収するためには、希少疾病用治療薬は高価になることが多く、そのために経済的な負担が懸念されます。

希少疾病用治療薬にはいくつかの種類があります。例えば、生物学的製剤、遺伝子治療薬、細胞治療薬などです。生物学的製剤は、生物由来の成分を利用した治療法であり、特に自己免疫疾患やがんなどに効果を示す場合があります。遺伝子治療は、遺伝子を導入することで疾病の根本原因に作用するアプローチであり、特定の遺伝性疾病に対して期待されています。細胞治療は、患者の細胞を改変したり、他の細胞を用いる方法で、再生医療の領域でも注目されています。

希少疾病用治療薬の用途は、主に以下のような分野で見られます。まず、遺伝性疾患、がん、代謝異常、神経疾患など、さまざまな種類の希少疾病に対する治療が行われています。これらの疾患は、往々にして症状が重篤で、患者の生活の質を大きく損なうことがあります。そのため、希少疾病用治療薬の開発が望まれています。

関連技術としては、バイオテクノロジーや製薬産業の発展が挙げられます。特に、遺伝子編集技術や先端的な製造技術の進展は、希少疾病用治療薬の開発に大きな影響を与えています。CRISPR-Cas9技術のような遺伝子編集手法は、新たな治療法の開発を加速させる要因となっています。また、人工知能（AI）や機械学習の活用により、疾患のメカニズムの解明や新たな治療ターゲットの発見が進められています。

希少疾病用治療薬に関連する規制や政策も重要です。多くの国では、希少疾病用薬を迅速に承認するための特別な制度が設けられており、例えば米国のFDAやEUのEMAでは、オーファンドラッグ指定制度が存在します。この制度により、開発企業にはインセンティブが与えられ、研究開発を促進するための支援が行われます。

希少疾病用治療薬の開発には課題も多く存在します。例えば、患者数が限られているために市販後の調査や長期的なデータ収集が難しく、治療効果や副作用に関する情報が不足しがちです。また、高価格やアクセスの制限も問題視されており、特に保険制度の違いによって患者の利益が不均等になることもあります。

さらに、患者の積極的な参加やコミュニティの形成も重要な要素です。患者団体や支援団体は、治療薬の研究開発や患者のニーズを企業に伝える役割を果たします。これにより、支援の手が差し伸べられ、患者自身の声が医薬品開発に反映されることが期待されます。

希少疾病用治療薬の市場は、今後も成長が見込まれています。製薬企業だけでなく、バイオテクノロジー企業やスタートアップが新たなアプローチで開発に参入し、革新的な治療法が生まれる可能性があります。また、患者や医療従事者との連携を強化することで、より効果的な治療法が実現されるでしょう。

このように、希少疾病用治療薬は、医療の現場で非常に重要な位置を占めています。その開発や普及を進めていくことは、多くの患者の生活の質を向上させるために不可欠であり、今後の医薬品開発においても注目される領域です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 希少疾病用治療薬の世界市場見通し2023年-2029年(Orphan Indication Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

希少疾病用治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp